Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | TFPI2 | P48307 | 2/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5194126 | 1.00 | SUCNR1 (0.42) | SUCNR1GRM2LMNAKDM4ETFPI2 | |
| SCHEMBL5195767 | 1.00 | SUCNR1 (0.42) | SUCNR1GRM2LMNAKDM4ETFPI2 | |
| SCHEMBL5584855 | 0.88 | — | — | |
| SCHEMBL8555632 | 0.88 | — | — | |
| SCHEMBL5196895 | 0.75 | RIPK1 (0.35) | TSHRALDH1A1 | |
| SCHEMBL5608543 | 0.75 | SMN1; SMN2 (0.39) | TP53TSHRALDH1A1 | |
| SCHEMBL8539572 | 0.74 | SUCNR1 (0.62) | SUCNR1LMNAKDM4ETFPI2GMNN | |
| SCHEMBL5608730 | 0.74 | EPHX1 (0.39) | HTT | |
| SCHEMBL5608583 | 0.72 | ALDH1A1 (0.33) | TSHRALDH1A1 | |
| SCHEMBL5608576 | 0.71 | GAA (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169944-B2 | Optically active epoxy compounds and processes for their production | TOSOH CORPORATION (JP) | 2007-01-30 | — | — | US | claimed |
| US-20040063979-A1 | Optically active epoxy compounds and processes for their production | TOSOH CORPORATION (JP) | 2004-04-01 | — | — | US | claimed |
| EP-1403260-A2 | Optically active epoxy compounds and processes for their production | Tosoh Corporation (JP) | 2004-03-31 | — | — | EP | claimed |
| US-7169944-B2 | Optically active epoxy compounds and processes for their production | TOSOH CORPORATION (JP) | 2007-01-30 | — | — | US | disclosed |
| JP-2004284992-A | PRODUCTION METHOD FOR OPTICALLY ACTIVE TRANS-3-CYCLOHEXYL-OXIRANECARBOXYLIC ACID | DAIICHI FINE CHEMICAL CO LTD | 2004-10-14 | — | — | JP | disclosed |
| US-20040063979-A1 | Optically active epoxy compounds and processes for their production | TOSOH CORPORATION (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1403260-A2 | Optically active epoxy compounds and processes for their production | Tosoh Corporation (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063979-A1 | Optically active epoxy compounds and processes for their production | CYP51A1, CYP11B1, PTGES | SUCNR1 4192/4885GRM2 4362/4885LMNA 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.